Triple negative breast cancer Trials in Oklahoma City, United States
Conditions / Triple negative breast cancer / Oklahoma City, United States
Triple negative breast cancer is a medical condition with active clinical research programs worldwide.
25 total trials for this combination
Showing top 10 of 25 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | COMPLETED | PHASE1 |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | COMPLETED | PHASE1/PHASE2 |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | RECRUITING | PHASE1/PHASE2 |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | TERMINATED | PHASE1 |
| NCT05377996 | A Study of XMT-1660 in Participants With Solid Tumors | RECRUITING | — |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | TERMINATED | PHASE1 |
| NCT05633654 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | RECRUITING | — |
| NCT02580448 | CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) | COMPLETED | PHASE1/PHASE2 |
| NCT02657889 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer | COMPLETED | PHASE1/PHASE2 |